Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer
(NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

Lung cancer continues to be a major global health problem; the disease is diagnosed in
more than 1.6 million new patients each year. However, significant progress is underway in …

Deep understanding of the genomic and immunological differences between Chinese and
Western lung cancer patients is of great importance for target therapy selection and …

Simple Summary In resected lung cancer, adjuvant and neoadjuvant chemotherapy
following surgery are currently mainly based on TNM classification. With the validation and …

Lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, is often
triggered by an aberration in a driver oncogene in tumor cells. Examples of such aberrations …

Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical
turning point for the treatment of lung tumors harboring kinase alterations suitable for …

Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib …